
143.00 Delayed Data As of Feb 01 | ![]() Today’s Change | 117.08 Today|||52-Week Range 189.07 | -4.81% Year-to-Date |
Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down Jan 31 / Zacks.com - Paid Partner Content | FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy Jan 27 / Zacks.com - Paid Partner Content |
The Covid sales boom is over for Pfizer Jan 31 / CNN.com | Can Pfizer (PFE) Beat Expectations This Earnings Season? Jan 26 / Zacks.com - Paid Partner Content |
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax Jan 30 / Zacks.com - Paid Partner Content | Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe Jan 26 / Zacks.com - Paid Partner Content |
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised) Jan 27 / Zacks.com - Paid Partner Content |
Previous close | 143.41 |
Today’s open | 142.02 |
Day’s range | 139.28 - 144.48 |
Volume | 746,599 |
Average volume (3 months) | 910,845 |
Market cap | $34.8B |
Earnings growth (last year) | +67,642.93% |
Earnings growth (this year) | -11.83% |
Earnings growth (next 5 years) | -47.70% |
Revenue growth (last year) | +3,979.40% |
P/E ratio | 3.3 |
Price/Sales | 2.98 |
Price/Book | 2.57 |
No competitors data available. |
Next reporting date | March 29, 2023 |
EPS forecast (this quarter) | $7.44 |
Annual revenue (last year) | $22.4B |
Annual profit (last year) | $12.2B |
Net profit margin | 54.24% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |